Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, Efficacy and Pharmacodynamics of KBSA301 in Severe Pneumonia (S. Aureus)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tosatoxumab (Primary)
Indications Methicillin-resistant Staphylococcus aureus infections; Pneumonia; Staphylococcal infections
Focus First in man; Therapeutic Use
Sponsors Aridis Pharmaceuticals

07 Nov 2018 According to an Aridis Pharmaceuticals media release, data from this trial was presented at the 31st Annual Congress of the European Society of Intensive Care Medicine and was published in the October 21, 2018 issue of the Intensive Care Medicine journal.
05 Jun 2017 According to an Aridis Pharmaceuticals media release, top-line results from the study have been presented at the 2017 ASM Microbe congress.
25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com